自然杀手细胞治疗市场报告（按治疗、应用、最终用户和地区划分）2025-2033

2024年，全球自然杀手细胞治疗市场规模达32亿美元。展望未来， IMARC Group预计到2033年，该市场规模将达到86亿美元，2025-2033年期间的复合年增长率（CAGR）为11.8%。癌症患病风险的上升以及老年人口的不断增长，正在推动市场的发展。

自然杀手细胞治疗市场趋势：

联合疗法日益普及

将NK细胞疗法与其他治疗方式结合以增强疗效的做法正日益受到关注。例如，Innate Pharma的抗CD22免疫毒素Lumoxiti与NK细胞联合使用，用于破坏并靶向毛细胞白血病中表达CD22的癌细胞。此外，这种方法充分利用了两种疗法的优势。此外，2024年5月，致力于开发用于自体免疫、癌症和传染病的创新细胞治疗平台的生物製药公司Coeptis Therapeutics Holdings, Inc.推出了SNAP-CAR NK细胞，用于靶向多种抗原。

监管部门批准不断增加

政府机构日益重视提高NK细胞生产的可靠性和效率，这已成为推动市场成长的重要因素。此外，政府机构也鼓励将实验室研究转化为可行的临床疗法，这将在可预见的未来持续推动市场发展。例如，2024年4月，新一代NK细胞疗法的领先创新者Ingenium Therapeutics获得了美国食品药物管理局（FDA）颁发的治疗急性髓性白血病（AML）的孤儿药资格认定。

即时监控需求不断成长

即时监测和资料分析广泛应用于NK细胞疗法的开发，正在提高治疗精准度和患者疗效。此外，像Bio-Techne的Ella系统这样的平台能够精确监测NK细胞扩增过程中细胞激素的产生，从而确保最佳的细胞功能。即时分析还允许研究人员动态调整培养条件，这有助于提高NK细胞的品质和有效性。这对市场产生了正面的影响。

目录

第一章：前言

第二章：范围与方法

• 研究目标
• 利害关係人
• 资料来源
  • 主要来源
  • 二手资料
• 市场评估
  • 自下而上的方法
  • 自上而下的方法
• 预测方法

第三章：执行摘要

第四章：简介

第五章：全球自然杀手细胞治疗市场

• 市场概况
• 市场表现
• COVID-19的影响
• 市场预测

第六章：市场区隔：按治疗学

• NK细胞疗法
• NK细胞定向抗体

第七章：市场区隔：依应用

• 癌症
• 胃肠道疾病
• 免疫增生性疾病
• 其他的

第 8 章：市场区隔：依最终用户

• 医院
• 研究中心和研究所
• 其他的

第九章：市场细分：依地区

• 北美洲
  • 美国
  • 加拿大
• 亚太
  • 中国
  • 日本
  • 印度
  • 韩国
  • 澳洲
  • 印尼
  • 其他的
• 欧洲
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙
  • 俄罗斯
  • 其他的
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 其他的
• 中东和非洲

第 10 章：SWOT 分析

第 11 章：价值链分析

第 12 章：波特五力分析

第十三章：价格分析

第 14 章：竞争格局

• 市场结构
• 关键参与者
• 关键参与者简介
  • Affimed GmbH
  • Bristol-Myers Squibb Company
  • Fate Therapeutics
  • Fortress Biotech Inc.
  • Glycostem Therapeutics
  • Innate Pharma SA
  • Kuur Therapeutics Inc. (Athenex Inc.)
  • Nkarta Inc.
  • Takeda Pharmaceutical Company Limited
  • Ziopharm Oncology Inc.

The global natural killer cells therapeutics market size reached USD 3.2 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 8.6 Billion by 2033, exhibiting a growth rate (CAGR) of 11.8% during 2025-2033. The rising risks of developing cancer, along with the expanding geriatric population, are propelling the market.

Natural Killer Cells Therapeutics Market Trends:

Increasing Popularity of Combination Therapies

Combining NK cell therapies with other treatment modalities to enhance therapeutic efficacy is gaining extensive traction. For example, Innate Pharma's Lumoxiti, an anti-CD22 immunotoxin, is adopted in conjunction with NK cells to destroy and target CD22-expressing cancer cells in hairy cell leukemia. Moreover, this approach leverages the strengths of both therapies. Besides this, in May 2024, Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company developing innovative cell therapy platforms for autoimmune, cancer, and infectious diseases, introduced SNAP-CAR NK cells to target multiple antigens.

Growing Regulatory Approval

The rising focus among government agencies on enhancing the reliability and efficiency of NK cell production is acting as a significant growth-inducing factor. Furthermore, they are encouraging the translation of laboratory research into viable clinical therapies, which will continue to fuel the market over the foreseeable future. For example, in April 2024, Ingenium Therapeutics, a leading innovator in next-generation NK cell therapies, received an Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatment of acute myeloid leukemia (AML).

Rising Demand for Real-Time Monitoring

The widespread integration of real-time monitoring and data analytics into NK cell therapy development is enhancing treatment precision and patient outcomes. Moreover, platforms like Bio-Techne's Ella system enable precise monitoring of cytokine production during NK cell expansion, thereby ensuring optimal cell functionality. Real-time analytics also allow researchers to adjust culture conditions dynamically, which aids in improving the quality and effectiveness of the NK cells produced. This is positively influencing the market.

Global Natural Killer Cells Therapeutics Industry Segmentation:

Breakup by Therapeutics:

• NK Cell Therapies
• NK Cell Directed Antibodies

Currently, NK cell directed antibodies hold the majority of the total market share

NK cell directed antibodies target natural killer cells to enhance their ability to recognize and destroy cancer cells. For example, Affimed's AFM13, a bispecific NK cell engager, targets CD30 on cancer cells and CD16A on NK cells.

Breakup by Application:

• Cancer
• Gastrointestinal Diseases
• Immunoproliferative Disorders
• Others

Cancer currently exhibits a clear dominance in the market

The inflating need for effective cancer treatments drives the segment's growth. Recent product launches have underscored the potential of NK cell-based therapies in oncology. For instance, Fate Therapeutics' FT596 is an off-the-shelf, iPSC-derived NK cell therapy designed to target multiple cancer types, including B-cell malignancies.

Breakup by End User:

• Hospitals
• Research Centers and Institutes
• Others

Currently, research centers and institutes hold the majority of the total market share

Research centers and institutes offer high-quality reagents and technologies that streamline NK cell research, which is increasing the natural killer cells therapeutics market share. For example, Bio-Techne's Cloudz Human NK Cell Expansion Kit allows researchers to expand NK cells ex vivo efficiently.

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

North America exhibits a clear dominance in the market

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

Advancements in biotechnology and a strong focus on innovative cancer treatments are primarily catalyzing the market in North America. According to the IMARC, the United States cancer immunotherapy market size is projected to exhibit a growth rate (CAGR) of 10.90% during 2024-2032. Besides this, collaborations between biotech firms are strengthening the regional market.

Competitive Landscape:

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major market companies have also been provided. Some of the key players in the market include:

• Affimed GmbH
• Bristol-Myers Squibb Company
• Fate Therapeutics
• Fortress Biotech Inc.
• Glycostem Therapeutics
• Innate Pharma S.A.
• Kuur Therapeutics Inc. (Athenex Inc.)
• Nkarta Inc.
• Takeda Pharmaceutical Company Limited
• Ziopharm Oncology Inc.

Key Questions Answered in This Report

• 1.What was the size of the global natural killer cells therapeutics market in 2024?
• 2.What is the expected growth rate of the global natural killer cells therapeutics market during 2025-2033?
• 3.What are the key factors driving the global natural killer cells therapeutics market?
• 4.What has been the impact of COVID-19 on the global natural killer cells therapeutics market?
• 5.What is the breakup of the global natural killer cells therapeutics market based on the therapeutics?
• 6.What is the breakup of the global natural killer cells therapeutics market based on the application?
• 7.What is the breakup of the global natural killer cells therapeutics market based on the end user?
• 8.What are the key regions in the global natural killer cells therapeutics market?
• 9.Who are the key players/companies in the global natural killer cells therapeutics market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Natural Killer Cells Therapeutics Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Therapeutics

• 6.1 NK Cell Therapies
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 NK Cell Directed Antibodies
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast

7 Market Breakup by Application

• 7.1 Cancer
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Gastrointestinal Diseases
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Immunoproliferative Disorders
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Others
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast

8 Market Breakup by End User

• 8.1 Hospitals
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Research Centers and Institutes
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Others
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia-Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 Affimed GmbH
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
    • 14.3.1.3 Financials
  • 14.3.2 Bristol-Myers Squibb Company
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
    • 14.3.2.3 Financials
    • 14.3.2.4 SWOT Analysis
  • 14.3.3 Fate Therapeutics
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
    • 14.3.3.3 Financials
  • 14.3.4 Fortress Biotech Inc.
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
    • 14.3.4.3 Financials
  • 14.3.5 Glycostem Therapeutics
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio
  • 14.3.6 Innate Pharma S.A.
    • 14.3.6.1 Company Overview
    • 14.3.6.2 Product Portfolio
    • 14.3.6.3 Financials
  • 14.3.7 Kuur Therapeutics Inc. (Athenex Inc.)
    • 14.3.7.1 Company Overview
    • 14.3.7.2 Product Portfolio
  • 14.3.8 Nkarta Inc.
    • 14.3.8.1 Company Overview
    • 14.3.8.2 Product Portfolio
    • 14.3.8.3 Financials
  • 14.3.9 Takeda Pharmaceutical Company Limited
    • 14.3.9.1 Company Overview
    • 14.3.9.2 Product Portfolio
    • 14.3.9.3 Financials
    • 14.3.9.4 SWOT Analysis
  • 14.3.10 Ziopharm Oncology Inc.
    • 14.3.10.1 Company Overview
    • 14.3.10.2 Product Portfolio
    • 14.3.10.3 Financials

List of Figures

• Figure 1: Global: Natural Killer Cells Therapeutics Market: Major Drivers and Challenges
• Figure 2: Global: Natural Killer Cells Therapeutics Market: Sales Value (in Billion USD), 2019-2024
• Figure 3: Global: Natural Killer Cells Therapeutics Market Forecast: Sales Value (in Billion USD), 2025-2033
• Figure 4: Global: Natural Killer Cells Therapeutics Market: Breakup by Therapeutics (in %), 2024
• Figure 5: Global: Natural Killer Cells Therapeutics Market: Breakup by Application (in %), 2024
• Figure 6: Global: Natural Killer Cells Therapeutics Market: Breakup by End User (in %), 2024
• Figure 7: Global: Natural Killer Cells Therapeutics Market: Breakup by Region (in %), 2024
• Figure 8: Global: Natural Killer Cells Therapeutics (NK Cell Therapies) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 9: Global: Natural Killer Cells Therapeutics (NK Cell Therapies) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 10: Global: Natural Killer Cells Therapeutics (NK Cell Directed Antibodies) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 11: Global: Natural Killer Cells Therapeutics (NK Cell Directed Antibodies) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 12: Global: Natural Killer Cells Therapeutics (Cancer) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 13: Global: Natural Killer Cells Therapeutics (Cancer) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 14: Global: Natural Killer Cells Therapeutics (Gastrointestinal Diseases) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 15: Global: Natural Killer Cells Therapeutics (Gastrointestinal Diseases) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 16: Global: Natural Killer Cells Therapeutics (Immunoproliferative Disorders) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 17: Global: Natural Killer Cells Therapeutics (Immunoproliferative Disorders) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 18: Global: Natural Killer Cells Therapeutics (Other Applications) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 19: Global: Natural Killer Cells Therapeutics (Other Applications) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 20: Global: Natural Killer Cells Therapeutics (Hospitals) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 21: Global: Natural Killer Cells Therapeutics (Hospitals) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 22: Global: Natural Killer Cells Therapeutics (Research Centers and Institutes ) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 23: Global: Natural Killer Cells Therapeutics (Research Centers and Institutes ) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 24: Global: Natural Killer Cells Therapeutics (Other End Users) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 25: Global: Natural Killer Cells Therapeutics (Other End Users) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 26: North America: Natural Killer Cells Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
• Figure 27: North America: Natural Killer Cells Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 28: United States: Natural Killer Cells Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
• Figure 29: United States: Natural Killer Cells Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 30: Canada: Natural Killer Cells Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
• Figure 31: Canada: Natural Killer Cells Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 32: Asia-Pacific: Natural Killer Cells Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
• Figure 33: Asia-Pacific: Natural Killer Cells Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 34: China: Natural Killer Cells Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
• Figure 35: China: Natural Killer Cells Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 36: Japan: Natural Killer Cells Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
• Figure 37: Japan: Natural Killer Cells Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 38: India: Natural Killer Cells Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
• Figure 39: India: Natural Killer Cells Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 40: South Korea: Natural Killer Cells Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
• Figure 41: South Korea: Natural Killer Cells Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 42: Australia: Natural Killer Cells Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
• Figure 43: Australia: Natural Killer Cells Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 44: Indonesia: Natural Killer Cells Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
• Figure 45: Indonesia: Natural Killer Cells Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 46: Others: Natural Killer Cells Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
• Figure 47: Others: Natural Killer Cells Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 48: Europe: Natural Killer Cells Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
• Figure 49: Europe: Natural Killer Cells Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 50: Germany: Natural Killer Cells Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
• Figure 51: Germany: Natural Killer Cells Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 52: France: Natural Killer Cells Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
• Figure 53: France: Natural Killer Cells Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 54: United Kingdom: Natural Killer Cells Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
• Figure 55: United Kingdom: Natural Killer Cells Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 56: Italy: Natural Killer Cells Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
• Figure 57: Italy: Natural Killer Cells Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 58: Spain: Natural Killer Cells Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
• Figure 59: Spain: Natural Killer Cells Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 60: Russia: Natural Killer Cells Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
• Figure 61: Russia: Natural Killer Cells Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 62: Others: Natural Killer Cells Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
• Figure 63: Others: Natural Killer Cells Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 64: Latin America: Natural Killer Cells Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
• Figure 65: Latin America: Natural Killer Cells Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 66: Brazil: Natural Killer Cells Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
• Figure 67: Brazil: Natural Killer Cells Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 68: Mexico: Natural Killer Cells Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
• Figure 69: Mexico: Natural Killer Cells Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 70: Others: Natural Killer Cells Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
• Figure 71: Others: Natural Killer Cells Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 72: Middle East and Africa: Natural Killer Cells Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
• Figure 73: Middle East and Africa: Natural Killer Cells Therapeutics Market: Breakup by Country (in %), 2024
• Figure 74: Middle East and Africa: Natural Killer Cells Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 75: Global: Natural Killer Cells Therapeutics Industry: SWOT Analysis
• Figure 76: Global: Natural Killer Cells Therapeutics Industry: Value Chain Analysis
• Figure 77: Global: Natural Killer Cells Therapeutics Industry: Porter's Five Forces Analysis

List of Tables

• Table 1: Global: Natural Killer Cells Therapeutics Market: Key Industry Highlights, 2024 and 2033
• Table 2: Global: Natural Killer Cells Therapeutics Market Forecast: Breakup by Therapeutics (in Million USD), 2025-2033
• Table 3: Global: Natural Killer Cells Therapeutics Market Forecast: Breakup by Application (in Million USD), 2025-2033
• Table 4: Global: Natural Killer Cells Therapeutics Market Forecast: Breakup by End User (in Million USD), 2025-2033
• Table 5: Global: Natural Killer Cells Therapeutics Market Forecast: Breakup by Region (in Million USD), 2025-2033
• Table 6: Global: Natural Killer Cells Therapeutics Market: Competitive Structure
• Table 7: Global: Natural Killer Cells Therapeutics Market: Key Players